T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

T2 Biosystems reports revenue growth, eyes FDA breakthroughs for expansion

T2 Biosystems demonstrated strong revenue growth and operational improvements in Q3 2024, driven by sepsis test panel sales and strategic partnerships.
While facing financial challenges and regulatory complexities, the company's focus on innovation and market expansion presents significant opportunities for future growth.
Overall, T2 Biosystems remains optimistic about its growth prospects, supported by advancements in its product pipeline and collaborations to combat healthcare challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

LEXINGTON, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans to explore the potential to develop a rapid molecular diagnostic test for detection of the monkeypox virus, including technical and commercial feasibility. Monkeypox is a rare disease caused by infection with the monkeypox virus that is part of the orthopoxvirus family of viruses, which also contains smallpox. The main symptom of monkeypox is a rash, but individuals may also present with flu like symptoms. A rapid and accurate diagnosis of monkeypox is essential to expedite treatment and to limit exposure and spread of the disease.

T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus

LEXINGTON, Mass., July 29, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ: TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to twelve new employees.

T2 Biosystems Reports Granting of Inducement Awards

LEXINGTON, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2022 after market close on Monday, August 15, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report Second Quarter 2022 Financial Results on August 15, 2022

LEXINGTON, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity Annual Growth Conference in Boston, Massachusetts.

T2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference

Agile Therapeutics

Iterum Therapeutics Plc

RedHill Biopharma

More penny stocks to watch under $1 The post Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Buy Now? 7 Hot Stocks Under $1 To Watch

Molecular Diagnostic Test for Early Detection of Lyme Disease Molecular Diagnostic Test for Early Detection of Lyme Disease

T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel

T2 Biosystems Inc (NASDAQ: TTOO) expects Q2 FY22 revenues of $5.8 million - $6.1 million, below the consensus of $6.87 million. The interim numbers include product revenue of $2.5 million - $2.7 million and research revenue of $3.3 million - $3.4 million.

T2 Biosystems Shares Slide As Interim Q2 Sales Trail Consensus

Implemented expense reductions including headcount during the second quarter Implemented expense reductions including headcount during the second quarter

T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results

LEXINGTON, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to appear on the Benzinga All Access show on Friday, June 17, 2022.

T2 Biosystems to Appear on the Benzinga All Access Show on June 17, 2022

LEXINGTON, Mass., June 10, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension until November 1, 2022, to regain compliance with Nasdaq's minimum bid price requirement, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”).

T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market

LEXINGTON, Mass., May 20, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Patent and Trademark Office has issued patent number 11,326,213 (the ‘213 Patent), “NMR Methods and Systems for the Rapid Detection of Tick-Borne Pathogens”. The ‘213 Patent covers the T2Lyme™ Panel, which identifies the bacteria that cause Lyme disease directly from a patient's blood in 3 to 5 hours. The T2Lyme Panel runs on the T2Dx Instrument®, the same instrument currently used to run the FDA-cleared T2Bacteria® and T2Candida® Panels.

T2 Biosystems Announces Issuance of U.S. Patent for Direct Detection of Lyme Disease

T2 Biosystems, Inc. (NASDAQ:TTOO ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Malcolm MacLeod - IR Philip Taylor - Gilmartin Group John Sperzel - Chairman and CEO John Sprague - CFO Brett Giffin - Chief Commercial Officer Conference Call Participants Benjamin Haynor - Alliance Global Partners Stephen Brozak - WBB Operator Good day, ladies and gentlemen, and welcome to the T2 Biosystems First Quarter 2022 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for questions and comments after the presentation.

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q1 2022 Results - Earnings Call Transcript

Results driven by strong sepsis-focused instrument placements in the United States Results driven by strong sepsis-focused instrument placements in the United States

T2 Biosystems Announces First Quarter 2022 Financial Results

Company has Filed an Appeal and will Present a Plan to Regain Compliance Company has Filed an Appeal and will Present a Plan to Regain Compliance

T2 Biosystems Announces Receipt of Nasdaq Delisting Notice

LEXINGTON, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the formation of its Scientific Advisory Board (SAB), comprising leading clinicians and researchers in the areas of infectious disease, laboratory medicine, and pharmacy. The newly formed SAB will provide insights regarding T2 Biosystems' clinical utilization, product pipeline, preclinical development, clinical research, clinical data generation, and strategic guidance to advance the Company's mission.

T2 Biosystems Announces Formation and Members of Scientific Advisory Board

LEXINGTON, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has submitted an application with the U.S. Food and Drug Administration (FDA) for Breakthrough Device Designation for the Company's T2Biothreat™ Panel.

T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for T2Biothreat Panel

LEXINGTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2022 after market close on Thursday, May 5, 2022. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report First Quarter 2022 Financial Results on May 5, 2022

The Biomedical Advanced Research and Development Authority (BARDA) is providing an additional $4.4 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems Inc (NASDAQ: TTOO)  If all contract options are exercised, the total potential.

T2 Biosystems Secures Additional BARDA Funding To Develop Blood Test Panels To Detect Sepsis-Causing Pathogens

Advances U.S. Clinical Trials for T2Biothreat and T2Resistance and Continued Development of Next-Generation Diagnostics for the Detection of Bloodstream Infections and Antimicrobial Resistance Advances U.S. Clinical Trials for T2Biothreat and T2Resistance and Continued Development of Next-Generation Diagnostics for the Detection of Bloodstream Infections and Antimicrobial Resistance

T2 Biosystems Announces BARDA Exercise of Contract Option 2B Valued at $4.4 Million

LEXINGTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it will host an Analyst and Investor Day on Tuesday, April 12, 2022, at 12:00pm ET. During the virtual session, the management team will focus on the Company's commercial strategy and product pipeline.

T2 Biosystems to Host Analyst and Investor Day on April 12, 2022

The company has ramped up its revenues and instrument placements and also initiated T2Biothreat and T2Resistance Panel clinical trials.

A Roadmap To T2 Biosystems Story

Maris-Tech

RISE Education Cayman

Can these penny stocks continue to climb in February? The post Hot Penny Stocks to Add to Your List With High Market Volatility  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Penny Stocks to Add to Your List With High Market Volatility

The T2 Biosystems Inc (NASDAQ: TTOO) stock is trending today. This is why.

T2 Biosystems (TTOO) Stock: Why Its Trending Today

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q4 2021 Results - Earnings Call Transcript

Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments Full Year 2021 Total Revenue Growth of 55%; Plans to Double Sepsis Revenue and T2Dx Instruments

News for T2 Biosystems Stock (TTOO)